A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

NCT02089451 ↗

Phase 1 Completed 21 enrolled Novo Nordisk A/S

RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic properties (the exposure of the trial drug in the body) of faster-acting insulin aspart (FIAsp) after different injection regions and routes of administration in healthy subjects.

Timeline

Start: 2014-03-17
Primary completion: 2014-06-06
Completion: 2014-06-06

Publications

Results Hovelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H. Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. Clin Drug Investig. 2017 May;37(5):503-509. doi: 10.1007/s40261-017-0499-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin aspart	Protein / enzyme biologic	0.02 iu/kg	Subcutaneous
Subject	insulin aspart	Protein / enzyme biologic	0.2 iu/kg	Subcutaneous

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications